Stocks
Neurocrine Biosciences (NBIX) EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 138.1 | 264.6 | 416.1 | 639.7 | 666.6 | 881.2 | ||
| Changes by years, y/y, % | -59% | +92% | +57% | +54% | +4% | +14.7% | |||
Neurocrine Biosciences. EBITDA US GAAP, bln rub
Neurocrine Biosciences. EBITDA US GAAP, changes, %
Neurocrine Biosciences. EBITDA US GAAP, sum by quarters, bln rub
Neurocrine Biosciences (NBIX) EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | 31.3 | 152.9 | 299.5 | 235.4 | 193.4 | 881.2 | |
| Changes by years, y/y, % | -72% | -1% | +57% | +30% | +518% | |||
| Changes by quarters, q/q, % | -83% | +388% | +96% | -21% | -18% | |||
